Target of anticancer agent
US7097977B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 14, 2000 |
| Grant date | Aug 29, 2006 |
| Priority date | — |
| Expiry date | Oct 17, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
To provide a mutant Rad51 paralog gene, wherein a protein encoded thereby shows an activity for enhancing sensitivity of a cell to a DNA-damaging factor; a mutant Rad51 paralog peptide showing the activity; a transformed cell having the gene; a screening method for a drug having a DNA-damaging action, comprising contacting a test substance with the transformed cell, and evaluating a response of the cell; and a screening method for a controlling agent for DNA repair, comprising contacting a test substance with a transformed cell having the Rad51 paralog gene, and evaluating a homologous recombination repair capacity. According to the present invention, there is enabled a screening of a novel anticancer agent which allows a more efficient therapy for a cancer, wherein the agent is an agent capable of enhancing the sensitivity of a cell to an anticancer agent comprising a DNA-damaging factor or an agent having a DNA-damaging action.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.